Compare Ascendis Pharma A/S (ASND) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Peloton Interactive Inc — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while Peloton Interactive Inc trades at $6.11 (market cap $2.54B). The key difference: Ascendis Pharma A/S is far larger — about 7× Peloton Interactive Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| ASND | PTON | |
|---|---|---|
Market Cap | $17.74B | $2.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $9.00 |
52-Week Low | $163.32 | $3.71 |
Enterprise Value | $18.11B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Peloton Interactive (PTON) trades at $5.86, down 1.35% on the day, showing signs of stabilization after a 96% decline from pandemic highs. The company reported positive operating cash flow of $333M in 2025 and is projected to achieve profitability in 2026 with $23M net income. Technical indicators show a bullish moving average trend while fundamentals reveal improving margins and declining losses, though the stock carries a high P/E ratio of 97.83. Recent developments include inclusion in the S&P SmallCap 600 index and appointment of a new CFO.
PTON presents a turnaround opportunity with improving cash flow and projected profitability, but faces significant execution risks amid declining revenue and negative shareholder equity. Analyst consensus is cautiously optimistic with a $7.50 price target representing 28% upside, though the company must demonstrate sustainable subscriber growth to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
